Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Levoleucovorin

FDA-approved product (powder, intravenous), marketed as Khapzory, Fusilev, Levoleucovorin Calcium.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Levoleucovorin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Anemia
  • Colorectal adenocarcinoma
  • Colorectal cancer
  • Colorectal carcinoma
  • Colorectal neoplasm
  • Osteosarcoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Detoxifying agents for antineoplastic treatment
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli67.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae43.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Levoleucovorin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Levoleucovorin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients

    NCT02069704 · start 2014-10-29

    Registered record
    Registry ID
    NCT02069704
    Conditions
    Metastatic Colorectal Cancer (mCRC)
    Interventions
    Bevacizumab biosimilar (BEVZ92); Avastin® (bevacizumab, reference product)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-10-29
    Completion
    2017-06
    Enrolment
    142

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Colorectal Cancer (mCRC)
    InterventionBevacizumab biosimilar (BEVZ92); Avastin® (bevacizumab, reference product)
    PhasePhase 1
    Registry statusCompleted

  • Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases

    NCT01834014 · start 2013-05

    Registered record
    Registry ID
    NCT01834014
    Conditions
    Liver Metastasis; Colorectal Cancer
    Interventions
    Bevacizumab; Cetuximab; L-OHP; l-LV; 5-FU; 5-FU
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-05
    Completion
    2017-03
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Metastasis; Colorectal Cancer
    InterventionBevacizumab; Cetuximab; L-OHP; l-LV +2 more
    PhaseNot applicable
    Registry statusCompleted

  • CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer

    NCT01835041 · start 2013-04

    Registered record
    Registry ID
    NCT01835041
    Conditions
    Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IV Pancreatic Cancer
    Interventions
    6,8-bis(benzylthio)octanoic acid; oxaliplatin; leucovorin calcium; irinotecan hydrochloride; fluorouracil; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-04
    Completion
    2023-03-16
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IV Pancreatic Cancer
    Intervention6,8-bis(benzylthio)octanoic acid; oxaliplatin; leucovorin calcium; irinotecan hydrochloride +2 more
    PhasePhase 1
    Registry statusCompleted

  • Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer

    NCT01051167 · start 2009-02

    Registered record
    Registry ID
    NCT01051167
    Conditions
    Metastatic Colorectal Cancer
    Interventions
    Cetuximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-02
    Completion
    2016-09
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Colorectal Cancer
    InterventionCetuximab
    PhasePhase 2
    Registry statusCompleted

  • Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer

    NCT00707889 · start 2008-10

    Registered record
    Registry ID
    NCT00707889
    Conditions
    Advanced Colorectal Cancer; Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum
    Interventions
    ABT-869; bevacizumab; oxaliplatin; folinic acid; fluorouracil; ABT-869
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-10
    Completion
    2012-05
    Enrolment
    159

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Colorectal Cancer; Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum
    InterventionABT-869; bevacizumab; oxaliplatin; folinic acid +2 more
    PhasePhase 2
    Registry statusCompleted

  • Combination Chemotherapy and Bevacizumab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer

    NCT00719797 · start 2008-07

    Registered record
    Registry ID
    NCT00719797
    Conditions
    Colorectal Cancer
    Interventions
    bevacizumab; fluorouracil; irinotecan hydrochloride; leucovorin calcium; oxaliplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-07
    Completion
    Not recorded
    Enrolment
    509

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    Interventionbevacizumab; fluorouracil; irinotecan hydrochloride; leucovorin calcium +1 more
    PhasePhase 3
    Registry statusCompleted

  • Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by Surgery

    NCT00660894 · start 2008-04

    Registered record
    Registry ID
    NCT00660894
    Conditions
    Colorectal Cancer
    Interventions
    folinate calcium; tegafur-uracil; tegafur-gimeracil-oteracil potassium
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-04
    Completion
    2015-07
    Enrolment
    1,535

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    Interventionfolinate calcium; tegafur-uracil; tegafur-gimeracil-oteracil potassium
    PhasePhase 3
    Registry statusCompleted

  • Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer

    NCT00861094 · start 2008-03

    Registered record
    Registry ID
    NCT00861094
    Conditions
    Esophageal Cancer
    Interventions
    cisplatin; 5-FU; oxaliplatin; radiation therapy; Folinic Acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2008-03
    Completion
    2012-12
    Enrolment
    266

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEsophageal Cancer
    Interventioncisplatin; 5-FU; oxaliplatin; radiation therapy +1 more
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Study of Oxaliplatin, Calcium Folinate, and 5-Fluorouracil as Neoadjuvant Chemotherapy for Resectable Advanced Gastric Cancer

    NCT00591045 · start 2008-01

    Registered record
    Registry ID
    NCT00591045
    Conditions
    Stomach Neoplasms; Gastric Cancer
    Interventions
    mFOLFOX
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2008-01
    Completion
    2012-12
    Enrolment
    263

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStomach Neoplasms; Gastric Cancer
    InterventionmFOLFOX
    PhasePhase 2
    Registry statusUnknown

  • Radiation Therapy, Chemotherapy, and Cetuximab Followed by Surgery, Chemotherapy, and Cetuximab in Treating Patients With Locally Advanced or Metastatic Rectal Cancer That Can Be Removed by Surgery

    NCT00541112 · start 2007-10-29

    Registered record
    Registry ID
    NCT00541112
    Conditions
    Colorectal Cancer
    Interventions
    cetuximab; capecitabine; fluorouracil; leucovorin calcium; oxaliplatin; adjuvant therapy; conventional surgery; neoadjuvant therapy; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2007-10-29
    Completion
    2010-01-29
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    Interventioncetuximab; capecitabine; fluorouracil; leucovorin calcium +5 more
    PhasePhase 2
    Registry statusTerminated

  • Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery

    NCT00321828 · start 2006-03

    Registered record
    Registry ID
    NCT00321828
    Conditions
    Colorectal Cancer
    Interventions
    bevacizumab; fluorouracil; leucovorin; oxaliplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-03
    Completion
    2012-12
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    Interventionbevacizumab; fluorouracil; leucovorin; oxaliplatin
    PhasePhase 2
    Registry statusCompleted

  • Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma

    NCT00974792 · start 2006-01

    Registered record
    Registry ID
    NCT00974792
    Conditions
    Lymphoma
    Interventions
    pegfilgrastim; rituximab; cyclophosphamide; cytarabine; doxorubicin hydrochloride; etoposide phosphate; ifosfamide; leucovorin calcium; methotrexate; vincristine sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2006-01
    Completion
    Not recorded
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    Interventionpegfilgrastim; rituximab; cyclophosphamide; cytarabine +6 more
    PhasePhase 2
    Registry statusUnknown

  • Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer

    NCT00112918 · start 2004-12

    Registered record
    Registry ID
    NCT00112918
    Conditions
    Colorectal Cancer
    Interventions
    Bevacizumab; Capecitabine; 5-Fluorouracil (5-FU); Leucovorin calcium; Oxaliplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-12
    Completion
    2012-06
    Enrolment
    3,451

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    InterventionBevacizumab; Capecitabine; 5-Fluorouracil (5-FU); Leucovorin calcium +1 more
    PhasePhase 3
    Registry statusCompleted

  • Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

    NCT00068250 · start 2003-07

    Registered record
    Registry ID
    NCT00068250
    Conditions
    Brain and Central Nervous System Tumors; Lymphoma
    Interventions
    rituximab; methotrexate; temozolomide 100 mg/m^2; temozolomide 150 mg/m^2; temozolomide 200 mg/m^2; radiation therapy; post-radiation therapy temozolomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2003-07
    Completion
    2016-12
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBrain and Central Nervous System Tumors; Lymphoma
    Interventionrituximab; methotrexate; temozolomide 100 mg/m^2; temozolomide 150 mg/m^2 +3 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Bortezomib, Fluorouracil, and Leucovorin Calcium in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery

    NCT00007878 · start 2000-09

    Registered record
    Registry ID
    NCT00007878
    Conditions
    Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    bortezomib; fluorouracil; leucovorin calcium; pharmacological study; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2000-09
    Completion
    Not recorded
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUnspecified Adult Solid Tumor, Protocol Specific
    Interventionbortezomib; fluorouracil; leucovorin calcium; pharmacological study +1 more
    PhasePhase 1
    Registry statusCompleted